Asterias Biotherapeutics, Inc. (AST): Stephen Lahue Cartt , CEO of Asterias Biotherapeutics, Inc. purchased 50,000 shares on Jun 10, 2016. The Insider buying transaction was reported by the company on Jun 13, 2016 to the Securities and Exchange Commission. The shares were purchased at $2.93 per share for a total value of $146,530.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 10, 2016, Alfred D Kingsley (director) purchased 4,000 shares at $2.93 per share price.On May 17, 2016, Natale S Ricciardi (director) purchased 14,706 shares at $3.39 per share price.Also, On May 17, 2016, Don M Bailey (director) purchased 88,235 shares at $3.39 per share price.On May 17, 2016, Richard T. Lebuhn (director) purchased 15,000 shares at $3.39 per share price.
Asterias Biotherapeutics Inc: On Friday, Jun 10, 2016 heightened volatility was witnessed in Asterias Biotherapeutics Inc which led to swings in the share price. The shares opened for trading at $2.85 and hit $3.01 on the upside , eventually ending the session at $3, with a gain of 2.39% or 0.07 points. The heightened volatility saw the trading volume jump to 3,34,910 shares. The 52-week high of the share price is $7.35 and the company has a market cap of $134 M . The 52-week low of the share price is at $2.36.
Company has been under the radar of several Street Analysts.Asterias Biotherapeutics Inc is Initiated by Chardan Capital Markets to Buy and the brokerage firm has set the Price Target at $5.50. The Rating was issued on May 23, 2016.Asterias Biotherapeutics Inc is Initiated by Rodman & Renshaw to Buy and the brokerage firm has set the Price Target at $12. The Rating was issued on Apr 25, 2016.
Asterias Biotherapeutics Inc. is a biotechnology company. The Company is focused in the field of regenerative medicine. It has three clinical stage product candidates: AST-OPC1 indicated for spinal cord injuries; AST-VAC2 indicated for lung cancer and AST-VAC1 indicated for prostate cancer and acute myelogenous leukemia. The Company’s product development is focused primarily on AST-OPC1 and AST-VAC2. The Company’s lead therapeutic program focuses on the development of AST-OPC1 for spinal cord injury. AST-OPC1 product consists of glial progenitor cells which are cells that become glial cells after injection. AST-VAC1 is an autologous product (using cells that come from the treated patient) consisting of mature antigen-presenting dendritic cells pulsed with ribonucleic acid (RNA) for the protein component of human telomerase (hTERT) and a portion of a lysosomal targeting signal (LAMP).